QualityStocksNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Partners with Leading Mechanical, Plant Engineering Firm

 Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is partnering with Dürr, one of the world’s leading mechanical and plant engineering firms. Durr brings extensive expertise in automation and digitalization to the partnership, which is designed to focus on MULN’s EV manufacturing footprint. According to the agreement, Dürr, which has extensive expertise in automation and digitalization, will support Mullen’s Advanced Manufacturing and Engineering Center (“AMEC”) with full integration for vehicle assembly and complete paint shop technologies; the engineering center is located in Tunica, Mississippi. “Dürr is a leading international manufacturing systems and technology provider for the automotive industry,” said Mullen Automotive CEO and chair David Michery in the press release. “Our Tunica facility will be a leading example of manufacturing automation. Our goal is to have the best and most efficient manufacturing footprint in the U.S., and Dürr is a key partner in achieving this effort.”

To view the full press release, visit https://ibn.fm/Mbln2  

About Mullen

Mullen is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), an Undervalued Opportunity for Investment

 

• Mydecine’s and CMPS’ stocks have been grossly undervalued largely due to a lack of understanding of the psychedelic space 
• The situation presents a unique opportunity for investment, as Roth Capital Partners issued a $3 buy rating for 2022
• Mydecine has put systems and infrastructure in place to bank on the growing PTSD treatment, smoking cessation, and the health and wellness apps market, in its drive to increase value for its shareholders

There has been a huge misunderstanding of the psychedelic space and the potential that this industry has, specifically regarding the treatment of Post-Traumatic Stress Disorder (“PTSD”) and smoking cessation. This has led to undervalued equities for key players within this space including, but not limited to Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) and Compass Pathways (NASDAQ: CMPS).

In October 2021, CMPS released findings from its open-label study of psilocybin therapy to treat depression among cancer patients. Of note was that with a single administration of the COMP360 psilocybin therapy, over half of the patients in the study achieved remission in depression systems, sustained over eight weeks (https://ibn.fm/jLei7).

Soon after this important announcement, the value of CMPS stock fell by almost 30%. The drop was attributed to two key aspects. Firstly, traders, as opposed to doctors, read the research and reacted to it negatively. CMPS’ research posted a 50% success rate in treatment-resistant, clinically depressed patients. These patients had to deal with five different clinical treatments with a 0% success rate before achieving a 50% success rate with CMPS.

Secondly, the audience lacked the understanding of data and science, prompting them to sell.

“People who really did not grasp the significance of the data, they decided to sell,” noted Elemer Piros, an analyst at Roth Capital Partners.

CMPS’s challenges also affect Mydecine, an enterprise working towards transforming the treatment of mental health disorders and addiction. Its use of novel psychedelic and non—psychedelic molecules for medical use shows great promise within the industry. Still, the stigma and misunderstanding of the products and what they can achieve comes.

As it stands, Mydecine’s stock is trading at $0.16. However, it is one of the few stocks projected to grow tremendously in value in 2022. For one, Mydecine is well-positioned within PTSD treatment, smoking cessation, and the health and wellness apps market, which are valued at a combined $50 billion. 

It is projected that by 2026, the global smoking cessation market will be valued at $63.99 billion, representing a CAGR of 16.9% over the forecast period (2018-2026) (https://ibn.fm/kOhy2). It is also estimated that the market for psychedelic therapeutics will be valued at $69 billion by 2025, representing a CAGR of 8.2%, indicating the clear growing interest in psychedelic therapeutic drugs (https://ibn.fm/cOxTm). The PTSD market is currently valued at $990 million, with tremendous potential for growth (https://ibn.fm/oOyiD).

Tapping into these markets with its technology shows Mydecine’s incredible value. Given its achievements so far and the plans it has already in place, Mydecine is grossly undervalued. This, in turn, presents a huge investment opportunity, a fact that is backed by Roth Capital Partners’ $3 buy rating issue (https://ibn.fm/WEdMU).

Mydecine has partnered with the Johns Hopkins University (“JHU”) for its phase 2/3 smoking cessation clinical trial set to launch in early 2022 in what promises to be the company’s most ambitious clinical study yet (https://ibn.fm/7zM0Q). In addition to their seamless phase 2/3 design, Mydecine plans to supply their lead drug candidate, MYCO-001, for Dr. Matthew Johnson’s NIDA grant-funded multi-site smoking cessation study (https://nnw.fm/fomME). With safety and efficacy data from both studies, Mydecine is well positioned to possibly bring a smoking cessation treatment to market as early as 2024.  

The company has filed a technology patent that allows for the creation of formulations that make use of nano-emulsion technology to enhance, stabilize and make repeatable properties of ingredients from traditional medicine. CEO Josh Bartch stated in a recent press release (https://ibn.fm/07SrX), “The compatibility of these formulas as patent-protected ingredients has Mydecine excited to develop a wide variety of licensing opportunities.” 

Mydecine’s most recent patent application covers a family of psilocin analogs, psilocybin’s active metabolite, with solutions to directly address precision in delivery control and shelf stabilization (https://ibn.fm/Dwax1). The company believes these improvements will enable safer more effective treatments and ultimately lead to acceptance and adoption of psychedelic medicine.  

All these moves indicate a company committed to achieving its goals and building value for its shareholders. Moreover, systems and infrastructure so far guarantee the company’s growth in the 2022 calendar year, making it a grossly undervalued company and a viable investment that promises significant returns.

For more information, visit the company’s website at www.Mydecine.com.

NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces General Meeting Voting, Publication of Key Article on CBN as Possible Glaucoma Treatment

 InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, held its general meeting on Dec. 17, 2021, and approved the election of all director nominees. Those elected will hold office until the next annual shareholder meeting or until their successors are elected or appointed. The company also noted that all of the matters outlined for consideration and approval in InMed’s notice of meeting and management information circular were approved. In addition, the company announced that an article discussing cannabinol (“CBN”) as a potential treatment option for glaucoma has been published in a peer-reviewed journal. The article, titled “Cannabinol Modulates Neuroprotection and Intraocular Pressure: A Potential Multi-Target Therapeutic Intervention for Glaucoma,” was published in the “Biochimica et Biophysical Acta” journal. The article concludes that, first, CBN may promote neuroprotection of cells in the retina that are responsible for vision, and second, the substance may normalize intraocular pressure by attenuating changes in the extracellular matrix proteins. “Having this research peer-reviewed and published in such a reputable journal is a significant milestone for InMed’s glaucoma development program,” said InMed scientific advisor Dr. Mauro Maccarrone in the press release. “This provides important external validation for the scientific community as the program advances towards human studies. We believe InMed’s INM-088 program has significant implications for neuroprotection within the glaucoma space and may lead to a potential new treatment for millions of people suffering from this condition worldwide.”

To view the full press releases, visit https://ibn.fm/gf6eQ and https://ibn.fm/SgLbL

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, please visit www.InMedPharma.com.  

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – StraightUp Resources Inc. (CSE: ST) (OTCQB: STUPF) Announces New CEO

 StraightUp Resources (CSE: ST) (OTCQB: STUPF), a public company engaged in the business of mineral exploration and the acquisition of mineral property assets in North America, has announced the appointment of a new CEO: Rod Husband. An accomplished entrepreneur and economic geologist with more than 30 years of experience in the international commodity and finance sectors, Husband has garnered impressive experience in the exploration and development of companies. He has served as director and officer of several Canadian public companies and has raised more than $150 million for those companies. “We are excited to have Mr. Husband’s caliber of leadership and operational experience on board, especially during this phase of the company’s growth and expansion into international markets,” said Mark Brezer, StraightUp’s president and director, in the press release. “This appointment strengthens management and brings a new layer of expertise to the team. Of further importance to the company is the recent news of our neighbors, Great Bear Resources Ltd., is potentially being acquired by Kinross Gold Corporation for well over a billion dollars. Our commitment to adding shareholder value remains our primary focus alongside of continued exploration into next year.”

To view the full press release, visit https://ibn.fm/2UbC2

About StraightUp Resources Inc.

StraightUp is engaged in the business of mineral exploration and the acquisition of mineral property assets in Canada and the U.S. Its objective is to locate and develop economic, precious and base metal properties of merit. StraightUp intends to conduct exploration on the RLX North, RLX South, Belanger and the Ferdinand Gold Project, all located in the Red Lake Mining Division, as well as the recently acquired Bear Head Gold Project, located within the Meen-Dempster Greenstone Belt of the Uchi Subprovince, approximately 80 kilometers west of the Pickle Lake Gold Camp. The company’s recently acquired West Cat Mine includes an unpatented mining claim on federal land, located in the historic Beatty Mountain Nevada Mining District/Nye County, Nevada, about 15 kilometers east of U.S. Route 95, approximately 20 kilometers from Beatty, Nevada, at the base of the Bare Mountain Range. For more information, visit www.StraightUpResources.com.

NOTE TO INVESTORS: The latest news and updates relating to STUPF are available in the company’s newsroom at https://ibn.fm/STUPF

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Strategic Media Agreement with SRAX Inc. (NASDAQ: SRAX)

 Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced its entry into an advertising and media agreement for media buys and digital marketing with SRAX (NASDAQ: SRAX). Under the agreement, SRAX will act as the agent for Lexaria and will engage and manage media companies to create advertising materials and distribute them on internet platforms as well as manage the flow of such media distributions. SRAX will employ leading-edge analytical algorithms in order to maximize engagement. “Lexaria is pleased to be working with SRAX to inform and engage a broad investor community in this significant, year-long media outreach campaign,” said Chris Bunka, CEO of Lexaria Bioscience. “Lexaria has made tremendous progress during 2021 and we expect even more significant advancement in 2022 and are pursuing the broadest possible investor involvement to ensure that Lexaria’s achievements are communicated to all investors.”

To view the full press release, visit https://ibn.fm/52b6b 

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce time of onset from one to two hours to minutes, and mask unwanted tastes. The technology is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 23 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF) Providing Alternative to Complex Hydrogen Fuel Obstacles for Carbon-Neutrality by 2050

 

• The hurdles and obstacles that hydrogen manufacturing still must contend with provide companies like FuelPositive with the ability to help facilitate the zero-emission goal by providing technology to produce and utilize green ammonia affordably
• The use of green ammonia not only helps facilitate the upcoming goal of The Hydrogen Economy but it also provides a more cost-efficient and stable option 
• The global green ammonia market was valued at $9.52 million in 2019 and is expected to grow at a CAGR of 53.9% over the 2020 to 2027 forecast period

The consensus at the recent UN COP26 Climate Change Conference in November 2021 was to attain carbon neutrality by 2050. Despite the number of hurdles and obstacles ahead, it was agreed that the stability of the world hangs in the balance of executing this goal. In the past, alternative renewable energy sources have been offered as a solution to the current state of the environment. The problem with alternatives like wind or solar energy is that the medium needed to keep them going is not always available. The “green” solution that has surfaced from the Climate Change Conference is what is being referred to as green hydrogen (https://ibn.fm/5uP7o).

Traditional methods of producing hydrogen rely on fossil fuels, creating what has been labeled as “grey hydrogen.” This method of producing grey hydrogen results in extensive pollution in the form of greenhouse gases. However, when fossil fuels are traded for renewable resources, hydrogen can be created without producing carbon emissions.

Regarding the future of green hydrogen, Columbia University’s energy policy expert Anne-Sophie Corbeau stated “Any forecast at this stage is highly uncertain, but it’s fair to say that there is a trend showing lower fossil fuel demand and higher hydrogen demand.”

Canadian-based clean energy solutions innovator FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) recognizes the potential that hydrogen has as a fuel source but also sees the potential setbacks that may surface as a result. The Hydrogen Economy, albeit the goal, still has challenges to overcome before it is a truly viable solution to replace fossil fuels and create the carbon-neutral outcome desired. Some of these challenges hydrogen production faces include:

• Requiring energy-intensive, highly polluting production
• Producing a highly-volatile end product
• Needing storage conditions that are kept under extremely high pressure and cryogenic temperatures
• Escaping at room temperature and making structures brittle
• Having a virtually non-existent distribution infrastructure
• Having severe transportation concerns attached

FuelPositive’s proprietary green ammonia production system, on the other hand, provides the solution to these hydrogen problems and more. Green ammonia needs less energy to produce than other methods of NH3 production, but with no carbon emissions. FuelPositive’s green ammonia stores 65% more hydrogen than the highly compressed hydrogen products. Given hydrogen’s current obstacles, the use of green ammonia can circumvent them – providing lower cost from start to finish, easier storage, easier transportation, and the existing ammonia infrastructure can be used.

FuelPositive’s green ammonia comes with multiple advantages, such as:

• Eliminates the fertilizer-related carbon emissions in agriculture
• Replaces fossil fuels used for transportation in large engines (like farm equipment, trucks and ships)
• Provides an affordable, convenient, and sustainable supply of hydrogen for fuel cells
• Offers long-term storage of excess electricity for energy grids
• Provides electricity to northern/remote communities
• Facilitates the shift to The Hydrogen Economy
• Produces significant carbon credits as a result of emission reduction
• Reduces the need for massive, highly polluting ammonia production factories and inefficient supply chains 

The benefits of green ammonia are becoming widely recognized, and the global market is expanding as a result. According to a MarketWatch research report, the global green ammonia sector was valued at $9.52 million in 2019 and is expected to grow at a CAGR of 53.9% over the 2020 to 2027 forecast period (https://ibn.fm/5jcFK). This is likely to increase as the world moves forward with the elimination of traditional fossil fuels, which are proven bad for the environment, and implements changes to facilitate the goal of carbon-neutrality by 2050.

For more information, visit the company’s website at www.FuelPositive.com.

NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php